HIV-1 Genotypic Drug Resistance Interpretation Rules – 2009 Spanish Guidelines
Carmen de Mendoza 1, Lourdes Anta 2, Federico García 2, María Jesús Pérez-Elías 2, Félix Gutiérrez 2, Josep M. Llibre 2, Luis Menéndez-Arias 2, David Dalmau 2, Vicente Soriano 3
1 Puerta de Hierro University Hospital, Madrid, Spain; 2 NULL; 3 UNIR Health Sciences School and Medical Center, Universidad Internacional de La Rioja, Madrid, Spain
*Correspondence: Carmen de Mendoza, Email not available
Abstract
Interpreting the results of drug resistance tests for HIV-1 is one of the most difficult tasks for bothclinicians and virologists. There are many amino acid changes in viral proteins influencing thesusceptibility to specific drugs, causing loss of activity or conversely hypersusceptibility. Moreover,the results of interactions derived from complex mutational patterns are difficult to predict. Differentinterpretation algorithms have been developed to facilitate the translation of information obtained inthe genotypes to clinicians. Controversy exists, however, regarding the impact of genotypic changesover the activity of many antiretroviral drugs. Based on virologic outcomes, scientific literature, andexpert opinion, the Drug Resistance Platform of the Spanish AIDS Research Network (RIS, Red deInvestigación en SIDA) has developed over the last years its own interpretation system. Herein, wepresent the 2009 guidelines, in which special efforts have been made to standardize the criteria forinterpreting resistance mutations for compounds within the same drug family and to facilitate theclinical interpretation of HIV-1 resistance genotypes.
